GSK PLC Sponsored ADR (NYSE:GSK) Shares Purchased by Natixis Advisors LLC

Key Points

• Natixis Advisors LLC increased its stake in GSK PLC by 6.9% in Q1, owning 367,045 shares valued at approximately $14.2 million.
• GSK reported an earnings per share (EPS) of $1.23 for the last quarter, surpassing the estimated $1.12, while revenue reached $10.64 billion, compared to expectations of $7.92 billion.
• The company announced a quarterly dividend of $0.4206, with a dividend yield of 4.5%, although it has a relatively high dividend payout ratio of 79.17%.

Natixis Advisors LLC boosted its stake in shares of GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 6.9% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 367,045 shares of the pharmaceutical company's stock after purchasing an additional 23,711 shares during the period. Natixis Advisors LLC's holdings in GSK were worth $14,219,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in GSK. Arkadios Wealth Advisors lifted its position in GSK by 13.7% during the first quarter. Arkadios Wealth Advisors now owns 62,026 shares of the pharmaceutical company's stock valued at $2,403,000 after buying an additional 7,468 shares in the last quarter. Eastern Bank raised its stake in shares of GSK by 57.0% in the 1st quarter. Eastern Bank now owns 1,426 shares of the pharmaceutical company's stock valued at $55,000 after acquiring an additional 518 shares during the period. Federated Hermes Inc. lifted its holdings in shares of GSK by 51.3% during the 1st quarter. Federated Hermes Inc. now owns 137,814 shares of the pharmaceutical company's stock valued at $5,339,000 after acquiring an additional 46,715 shares in the last quarter. Mackenzie Financial Corp purchased a new stake in GSK during the 1st quarter worth $5,974,000. Finally, LPL Financial LLC boosted its position in GSK by 11.8% during the 1st quarter. LPL Financial LLC now owns 673,814 shares of the pharmaceutical company's stock worth $26,104,000 after purchasing an additional 70,929 shares during the period. Institutional investors and hedge funds own 15.74% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. Berenberg Bank reaffirmed a "hold" rating on shares of GSK in a research report on Tuesday, June 3rd. BNP Paribas assumed coverage on GSK in a report on Tuesday, April 15th. They issued a "neutral" rating and a $35.25 price target for the company. Hsbc Global Res upgraded shares of GSK to a "strong sell" rating in a research note on Monday, April 28th. Finally, Wall Street Zen raised shares of GSK from a "hold" rating to a "buy" rating in a research report on Sunday. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $37.38.

GSK Stock Up 2.3%

Shares of GSK stock traded up $0.85 during trading on Thursday, reaching $37.60. The company had a trading volume of 3,709,517 shares, compared to its average volume of 5,314,886. The company has a market cap of $76.71 billion, a price-to-earnings ratio of 17.41, a price-to-earnings-growth ratio of 1.63 and a beta of 0.51. The firm's fifty day moving average is $38.85 and its 200-day moving average is $37.75. The company has a debt-to-equity ratio of 1.07, a quick ratio of 0.57 and a current ratio of 0.87. GSK PLC Sponsored ADR has a fifty-two week low of $31.72 and a fifty-two week high of $44.67.

GSK (NYSE:GSK - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.12 by $0.11. GSK had a return on equity of 49.22% and a net margin of 10.81%. The firm had revenue of $10.64 billion for the quarter, compared to analysts' expectations of $7.92 billion. During the same period last year, the business posted $0.43 earnings per share. The firm's revenue for the quarter was up 1.3% on a year-over-year basis. On average, analysts anticipate that GSK PLC Sponsored ADR will post 4.14 EPS for the current year.

GSK Cuts Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, October 9th. Shareholders of record on Friday, August 15th will be paid a $0.4206 dividend. This represents a $1.68 dividend on an annualized basis and a yield of 4.5%. The ex-dividend date is Friday, August 15th. GSK's payout ratio is presently 77.78%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.